当前位置: 首页 >> 检索结果
235. Diabetes and Cause-Specific Mortality in Mexico City.
作者: Jesus Alegre-Díaz.;William Herrington.;Malaquías López-Cervantes.;Louisa Gnatiuc.;Raul Ramirez.;Michael Hill.;Colin Baigent.;Mark I McCarthy.;Sarah Lewington.;Rory Collins.;Gary Whitlock.;Roberto Tapia-Conyer.;Richard Peto.;Pablo Kuri-Morales.;Jonathan R Emberson.
来源: N Engl J Med. 2016年375卷20期1961-1971页
Most large, prospective studies of the effects of diabetes on mortality have focused on high-income countries where patients have access to reasonably good medical care and can receive treatments to establish and maintain good glycemic control. In those countries, diabetes less than doubles the rate of death from any cause. Few large, prospective studies have been conducted in middle-income countries where obesity and diabetes have become common and glycemic control may be poor.
236. Palbociclib and Letrozole in Advanced Breast Cancer.
作者: Richard S Finn.;Miguel Martin.;Hope S Rugo.;Stephen Jones.;Seock-Ah Im.;Karen Gelmon.;Nadia Harbeck.;Oleg N Lipatov.;Janice M Walshe.;Stacy Moulder.;Eric Gauthier.;Dongrui R Lu.;Sophia Randolph.;Véronique Diéras.;Dennis J Slamon.
来源: N Engl J Med. 2016年375卷20期1925-1936页
A phase 2 study showed that progression-free survival was longer with palbociclib plus letrozole than with letrozole alone in the initial treatment of postmenopausal women with estrogen-receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. We performed a phase 3 study that was designed to confirm and expand the efficacy and safety data for palbociclib plus letrozole for this indication.
|